ClearOne to Acquire Vivani Medical’s Cortigent in Merger Deal to Advance Neurostimulation Technologies
ClearOne,has announced a transformative strategic transaction that will significantly reshape the company’s future direction. The communications technology company has entered into a definitive Agreement and Plan of Merger with Cortigent, Inc., a wholly owned subsidiary of Vivani Medical, paving the way for Cortigent to become a wholly owned subsidiary of ClearOne upon completion of the transaction.
The agreement represents a major milestone for all parties involved, particularly as it positions ClearOne to expand into the rapidly evolving neurostimulation and neurotechnology market. The acquisition underscores the growing interest in advanced medical technologies designed to restore critical neurological functions, including vision and motor control, through precision neurostimulation.
Strategic Shift Toward Medical Innovation
The proposed merger marks a significant strategic evolution for ClearOne. Traditionally recognized for its professional audio and communication solutions, the company is now positioning itself to participate in one of healthcare’s most promising innovation sectors.
Following completion of the transaction, Cortigent will operate as a wholly owned subsidiary of ClearOne, enabling the combined organization to focus on advancing innovative neurostimulation technologies aimed at addressing severe neurological disorders and restoring lost sensory and motor functions.
The transaction reflects increasing investor and industry interest in companies developing implantable neurotechnology solutions capable of improving quality of life for patients affected by debilitating neurological conditions.
Financing to Support Future Growth
As part of the merger agreement, ClearOne has also committed to launching a substantial financing initiative designed to strengthen the financial position of the combined organization.
The company plans to file a Registration Statement on Form S-1 to conduct a public financing concurrently with the closing of the merger. The financing is expected to raise between $10 million and $15 million, providing the capital necessary to support ongoing product development, research initiatives, regulatory activities, and corporate operations.
This planned capital raise is viewed as a critical component of the overall transaction, ensuring that the combined company possesses sufficient financial resources to execute its long-term strategic objectives.
Management expects the proceeds from the financing to provide a strong operational foundation while supporting the advancement of Cortigent’s product pipeline and commercialization efforts.
Focus on Precision Neurostimulation
At the center of the transaction is Cortigent’s specialized expertise in precision neurostimulation.
Neurostimulation technologies involve the use of carefully controlled electrical impulses to stimulate specific regions of the nervous system. These therapies have emerged as an important area of medical innovation for treating neurological disorders that previously had limited therapeutic options.
Cortigent’s mission focuses on restoring essential neurological functions through sophisticated implantable technologies designed to help patients recover vision and improve motor abilities.
Such technologies have the potential to address substantial unmet medical needs affecting individuals who have experienced severe neurological injury or disease. By leveraging advanced engineering and neuroscience, precision neurostimulation systems seek to reconnect damaged neural pathways or bypass impaired neurological circuits, ultimately restoring functional capabilities.
The growing field of neurotechnology has attracted significant attention from clinicians, researchers, investors, and regulatory agencies due to its potential to transform treatment approaches for a wide variety of neurological disorders.
Addressing Significant Unmet Medical Needs
Millions of patients worldwide continue to live with neurological impairments that severely affect their independence and quality of life.
Loss of vision, impaired motor control, paralysis, and other neurological deficits often result from traumatic injuries, stroke, degenerative diseases, or other conditions affecting the nervous system.
Traditional treatment options frequently offer only limited improvements, leaving substantial unmet clinical needs.
Precision neurostimulation represents one of the most promising approaches to addressing these challenges by directly interfacing with the nervous system to restore function rather than simply managing symptoms.
Developers in this field continue to pursue next-generation implantable devices capable of delivering increasingly sophisticated therapeutic stimulation with improved precision, durability, and patient outcomes.
Cortigent’s technology platform is intended to contribute meaningfully to these ongoing advances.
Leadership Expresses Confidence
Commenting on the announcement, Eric Robinson, Chairman of ClearOne’s Board of Directors, expressed strong enthusiasm regarding the strategic rationale behind the merger.
According to Robinson, the board views Cortigent’s mission as highly compelling due to both the technical potential of its neurostimulation platform and the significant medical needs it seeks to address.
He emphasized that helping patients regain vision and motor function represents an important opportunity to improve lives while advancing innovative medical technology.
Robinson further stated that ClearOne believes it represents the strongest path forward for supporting Cortigent’s continued development and enabling the next phase of its corporate growth.
He also noted that the planned financing is expected to provide the combined company with the financial resources necessary to continue advancing its product development pipeline.
Importantly, Robinson indicated that the decision to approve the merger received unanimous support from ClearOne’s Board of Directors, reflecting the board’s confidence in the transaction’s strategic value.
He added that company leadership believes the agreement represents a meaningful opportunity not only for shareholders but also for Cortigent’s employees and, ultimately, for patients who could benefit from the company’s neurotechnology innovations.
Creating Long-Term Shareholder Value
Beyond its scientific and clinical implications, the transaction is also intended to create long-term value for shareholders.
By combining ClearOne’s corporate infrastructure with Cortigent’s medical technology portfolio, the merged company aims to establish a platform capable of supporting sustained innovation and future commercial growth.
Healthcare investors have increasingly focused on companies developing novel therapies in high-growth medical technology segments, including implantable devices, neurotechnology, digital therapeutics, and precision medicine.
Should Cortigent successfully advance its development programs, the combined company may benefit from participation in these expanding healthcare markets.
The planned financing further demonstrates management’s intention to ensure adequate capitalization while pursuing future development milestones.
Expanding Presence in the Neurotechnology Market
The neurotechnology industry has experienced considerable momentum over the past decade.
Rapid advances in neuroscience, biomedical engineering, artificial intelligence, microelectronics, and implantable device design have accelerated the development of increasingly sophisticated therapeutic platforms.
Medical device companies worldwide continue investing heavily in brain-computer interfaces, spinal cord stimulation systems, deep brain stimulation technologies, retinal implants, and peripheral nerve stimulation devices.
These innovations are opening new possibilities for treating neurological disorders that were previously considered irreversible.
As regulatory agencies continue evaluating novel neurotechnology solutions and clinical evidence expands, market analysts anticipate continued growth across multiple therapeutic applications.
By acquiring Cortigent, ClearOne positions itself to participate in this rapidly developing healthcare sector.
Importance of Capital Access
Access to sufficient capital remains essential for medical technology companies developing innovative implantable devices.
Clinical studies, engineering development, manufacturing scale-up, regulatory submissions, quality system implementation, and commercialization efforts all require significant investment over extended periods.
The anticipated $10 million to $15 million financing is therefore expected to play a critical role in supporting the combined company’s operational roadmap.
Funding will likely enable continued product refinement, regulatory planning, research activities, and broader organizational development as the company advances toward future commercialization opportunities.
Transaction Subject to Closing Conditions
Like most corporate mergers, completion of the transaction remains subject to customary closing conditions outlined in the definitive merger agreement.
These conditions generally include regulatory requirements, financing completion, and satisfaction of various legal and contractual obligations before the transaction can officially close.
Upon successful completion, Cortigent will become a wholly owned subsidiary of ClearOne, officially bringing together the companies under a unified corporate structure.
The financing initiative is expected to occur concurrently with the closing, providing immediate financial support for post-merger operations.
The merger between ClearOne and Cortigent represents a pivotal moment for both organizations.
For ClearOne, the transaction marks a strategic transformation from its historical communications technology business toward participation in advanced healthcare innovation. For Cortigent, the agreement provides access to additional financial resources and corporate support necessary to continue advancing its precision neurostimulation technologies.
As the combined organization moves forward, management intends to focus on advancing therapies designed to restore critical neurological functions for patients facing severe disabilities.
With planned financing, unanimous board support, and a shared commitment to innovation, the companies believe the transaction establishes a strong foundation for future growth.
If completed as planned, the merger has the potential to position the combined company as an emerging participant in the growing neurotechnology market while advancing the development of therapies that could significantly improve the lives of patients affected by neurological disorders.
Source link: https://www.businesswire.com/
